Objective Interleukin-10 (IL-10) is a major immunoregulatory cytokine and its gene plays a fundamental role in anti-inflammatory and immunosuppressive activity. This study aimed to examine the association between the IL10 gene promoter -1082G/A polymorphism (rs1800896) and tardive dyskinesia (TD) in schizophrenia.Methods Two hundred and eighty unrelated Korean schizophrenic patients participated in this study (105 TD and 175 non-TD patients). TD was diagnosed using the Research Diagnostic Criteria for TD and Abnormal Involuntary Movement Scale (AIMS). Genotyping was performed by RT-PCR and high-resolution melting curve analysis.Results The distributions of genotypic frequencies did not differ between patients with and without TD (χ2=4.33, p=0.115). However, allelic frequencies of the two groups were different (χ2=4.45, p=0.035); the A allele frequency was higher in TD. The total AIMS scores of the three genotypes were not different (F=1.33, p=0.266). However, the total AIMS scores of the A allele carrier and the A allele non-carrier were significantly different (t=5.79, p<0.001). Logistic regression analaysis showed that IL10 -1082G/A genotype significantly predicts presence of TD (p=0.045) after adjusting for covariates such as age and treatment duration.Conclusion This finding suggests that the A allele of rs1800896 may be associated with TD development following a low IL-10 function.

Objective: To assess the feasibility, acceptability, and preliminary effects of circadian rhythm for sleep (CRS), a mobile digital therapeutic that delivers closed-loop, wearable- and light-sensor–driven circadian coaching for insomnia. Methods: Six-week, single-arm feasibility study in adults with short-term or chronic insomnia. CRS provided daily recommendations emphasizing stable wake-up time, morning light exposure, and daytime activity. Feasibility and acceptability outcomes were assessed (completion, passive-sensor data capture/adherence, satisfaction), and the primary clinical outcome (exploratory) was change in Insomnia Severity Index (ISI) from baseline to Week 6; the key secondary clinical outcome (exploratory) was Pittsburgh Sleep Quality Index (PSQI). Objective sleep–wake metrics from wearable device were explored. Results: Twenty-three participants were enrolled; 20 completed the program (87.0%), and 16 comprised the prespecified analysis set based on data-fidelity criteria. Among these 16 participants, valid passive sensor data from the wearable and light sensors were captured on 88.6% of study days. ISI significantly improved from baseline to Week 6 (median 21.0 → 14.0; p < .001 by within-subject analysis), and PSQI improved (mean 10.9 → 7.7; p < .001; partial η ² ≈ 0.50). Objective wearable metrics (total sleep time, time-in-bed, sleep onset, wake time) did not change significantly over time in this short pilot. Satisfaction was favorable (mean 37.9/45). No adverse events occurred. Conclusions: CRS was feasible and acceptable, and was associated with within-subject improvements in subjective insomnia symptoms in this single-arm feasibility study; however, because there was no control group, these findings are preliminary and hypothesis-generating, supporting further evaluation in larger randomized controlled trials. Trial registry name: Clinical Research Information Service URL: https://cris.nih.go.kr Trial registration number: KCT0010801

Objective: To determine the feasibility and efficacy of cognitive behavioral therapy for insomnia (CBT-I) in patients with schizophrenia without prior psychotic symptom aggravation.Methods: This prospective single-arm trial included 31 patients diagnosed with schizophrenia and insomnia who received CBT-I. We provided four weekly 60-min sessions of group or individual CBT-I. All patients completed several sleep-related scale assessments before and 2, 3, and 4 weeks after treatment: the Korean version of Pittsburgh Sleep Quality Index (PSQI-K), Insomnia Severity Index (ISI), Korean version of the Epworth Sleepiness Scale (K-ESS), Dysfunctional Beliefs and Attitudes about Sleep Scale-16 (DBAS-16), and sleep diary. The primary outcome was insomnia symptom changes over the treatment period, as indicated by the PSQI-K, ISI, sleep onset latency, and total sleep time from the sleep diary. The secondary outcome was improvement in maladaptive cognition associated with sleep, as indicated by the DBAS-16.Results: The total PSQI-K and ISI at each timepoint showed significant improvements over the CBT-I program period. The total K-ESS and DBAS-16 scores showed significant improvement over the treatment period. Sleep onset latency was significantly shortened; however, no significant changes were noted in the total sleep time and some PSQI-K subscales (sleep duration, use of sleep medication, and daytime dysfunction).Conclusion: Our findings suggest the efficacy of CBT-I in improving insomnia symptoms, dysfunctional beliefs, and attitudes toward sleep in patients with schizophrenia with relatively stable psychotic symptoms. Therefore, further large randomized controlled trials are warranted to provide precise estimates of the effects of CBT-I in this patient population.

Precise chronological transition is critical for a normal female reproductive system. Many epidemiologic studies have demonstrated rhythmicity in parturition during the resting phase, and even seasonal breeding. Circadian rhythms are controlled by a multi-oscillatory circadian system. These rhythms are determined by both genetic and environmental factors. The female reproductive axis is also highly rhythmic, and the hypothalamic-pituitary-gonadal axis and the hypothalamic-pituitary-adrenal axis are also functional multi-oscillatory circadian systems. Bidirectional communication between the central and peripheral tissue clocks is essential for maintaining the rhythm from ovulation to parturition. This review discusses the circadian timing of the female reproductive system, specifically its underlying metabolic and molecular clock functions. This review particularly focused on the following areas: multi-oscillatory system in the female reproductive system; the ovarian cycle and the timing of ovulation; timing of mating and seasonal reproduction; circadian rhythms in pregnancy; circadian timing of labor onset and parturition.